<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04316390</url>
  </required_header>
  <id_info>
    <org_study_id>ABW-2020-OS2</org_study_id>
    <nct_id>NCT04316390</nct_id>
  </id_info>
  <brief_title>Influence of Hesperidin and Vitamin C on Uric Acid Concentration</brief_title>
  <acronym>HesperiDrinC</acronym>
  <official_title>Influence of Hesperidin and Vitamin C on Uric Acid Concentration</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Kiel</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Hochschule Geisenheim University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Kiel</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Aim of the study is to investigate the impact of hesperidin and/or vitamin C on elevated uric
      acid concentrations.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Duration of the study is 9 weeks. 1) a washout week, 2) two intervention weeks, 3) four weeks
      washout period, 4) two intervention weeks.

      The study is conducted under free living conditions. During washout weeks consumption of
      orange juice or citrus fruits or vitamin C containing supplements is restricted.

      During intervention weeks 200 mL of study drink is consumed daily. And participants are asked
      to maintain their normal physical activity and habitual diet. Additional citrus or vitamin C
      containing beverages are not allowed.

      At the beginning and the end of each intervention phase uric acid, insulin sensitivity, blood
      pressure, pulse wave velocity and bioavailability of hesperidin are assessed.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">October 2020</start_date>
  <completion_date type="Anticipated">December 2021</completion_date>
  <primary_completion_date type="Anticipated">August 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Changes in uric acid serum concentrations</measure>
    <time_frame>Baseline (pre) and post two weeks of intervention</time_frame>
    <description>measured via uric acid serum concentration (mg/dL)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>changes in uric acid excretion</measure>
    <time_frame>Baseline (pre) and post two weeks of intervention</time_frame>
    <description>measured via uric acid excretion in 24h urine (mg/24h)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>changes in pulse wave velocity</measure>
    <time_frame>Baseline (pre) and post two weeks of intervention</time_frame>
    <description>measured via oscillometric method (m/s)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>insulin sensitivity</measure>
    <time_frame>Baseline (pre) intervention periods</time_frame>
    <description>measured via minimal model from oral glucose tolerance test data using the particular study drink with added glucose to 75 g Glucose / 200 mL</description>
  </secondary_outcome>
  <other_outcome>
    <measure>bioavailability of hesperidin in blood</measure>
    <time_frame>Baseline (pre) and post two weeks of intervention</time_frame>
    <description>detection of hesperidin metabolites measured via chromatography and following mass spectrometry in serum</description>
  </other_outcome>
  <other_outcome>
    <measure>bioavailability of hesperidin in urine</measure>
    <time_frame>Baseline (pre) and post two weeks of intervention</time_frame>
    <description>detection of hesperidin metabolites measured via chromatography and following mass spectrometry in 24h urine</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Higher Uric Acid Concentrations (&gt;5,5 mg/dl)</condition>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Hesperidin (A)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>study drink without hesperidin and without vitamin C compared to study drink with hesperidin</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Hesperidin + Vitamin C (B)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>study drink with vitamin C compared to study drink with hesperidin and vitamin C</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Control</intervention_name>
    <description>study drink (two weeks)</description>
    <arm_group_label>Hesperidin (A)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Hesperidin</intervention_name>
    <description>study drink + Hesperidin 600 mg (two weeks)</description>
    <arm_group_label>Hesperidin (A)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Vitamin C</intervention_name>
    <description>study drink + Vitamin C 250 mg (two weeks)</description>
    <arm_group_label>Hesperidin + Vitamin C (B)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Hesperidin + Vitamin C</intervention_name>
    <description>study drink + Hesperidin 600 mg + Vitamin C 250 mg (two weeks)</description>
    <arm_group_label>Hesperidin + Vitamin C (B)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  healthy

          -  higher uric acid concentration (≥5.5 mg/dL)

          -  Informed written consent

        Exclusion Criteria:

          -  pregnancy

          -  fructose intolerance

          -  smoking

          -  gout or medicated hyperuricemia

          -  diabetes mellitus

          -  antidiabetic or cytostatic medication

          -  weight loss (≥5% in the past 3 months)

          -  consumption of vitamin C-containing supplements

          -  parallel participation in a clinical trial

          -  anemia and / or iron deficiency
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Anja Bosy-Westphal, Prof, PhD, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Institute of Human Nutrition, Kiel University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Anja Bosy-Westphal, Prof, PhD, MD</last_name>
    <phone>+494318805674</phone>
    <email>abosyw@nutrition.uni-kiel.de</email>
  </overall_contact>
  <verification_date>May 2020</verification_date>
  <study_first_submitted>March 12, 2020</study_first_submitted>
  <study_first_submitted_qc>March 19, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">March 20, 2020</study_first_posted>
  <last_update_submitted>May 27, 2020</last_update_submitted>
  <last_update_submitted_qc>May 27, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">May 28, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Kiel</investigator_affiliation>
    <investigator_full_name>Prof. Dr. Dr. Anja Bosy-Westphal</investigator_full_name>
    <investigator_title>Prof. Dr. Dr. Anja Bosy-Westphal</investigator_title>
  </responsible_party>
  <keyword>hesperidin</keyword>
  <keyword>vitamin C</keyword>
  <keyword>uric acid concentration</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vitamins</mesh_term>
    <mesh_term>Ascorbic Acid</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

